James Peyer

James Peyer earned a PhD in stem‑cell biology at the University of Texas Southwestern before turning to venture creation. After a stint at McKinsey’s biotech practice he founded Cambrian Bio, a ‘hub‑and‑spoke’ drug‑discovery studio that builds subsidiary companies around individual longevity mechanisms. Cambrian has raised more than $160 million and seeded over a dozen programs, including senolytic peptides, autophagy inducers, and next‑generation rapalogs. Peyer’s capital‑efficient model spreads risk across multiple shots on goal while sharing a common CMC and regulatory backbone. He is a frequent speaker at Milken, Rejuvenation Startup Summit, and hosts the ‘Cambrian Catalyst’ newsletter, making him a connective node between academia, venture capital, and pharma.